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PENILAIAN EKSPRESI mRNA RESEPTOR DOPAMIN DRD4 DAN DRD5 
DI DALAM SEL LIMFOSIT PERIFERI DI KALANGAN SUBJEK LELAKI 
MELAYU DENGAN PERGANTUNGAN CAMPURAN JENIS OPIAT DAN 
PERANSANG AMFETAMIN YANG SEDANG MENJALANI TERAPI 
GANTIAN METHADONE  
 ABSTRAK  
 
Di Malaysia dan lain-lain negara Asia, taburan pergantungan kepada campuran 
opiat dan peransang jenis amfetamin adalah tinggi dan telah menjadi masalah besar 
kesihatan. Opiat dan peransang jenis amfetamin menghasilkan tindakbalas untuk 
mencapai tujuan utama iaitu meningkatkan aras dopamin yang tinggi di luar sel di 
dalam otak dan akhirnya akan memberi kesan ganjaran dadah. Tindakbalas dopamin 
berlaku melalui perantaraan reseptor yang khusus yang berpasangan dengan protin G 
yang terdiri daripada 2 jenis yang berbeza; jenis D1 reseptor (D1 dan D5) dan jenis D2 
reseptor (D2, D3 dan D4). Bukti dari kajian-kajian lepas telah mencadangkan bahawa 
sistem dopamin periferi mencerminkan aktiviti dan patologi sistem dopamin pusat, 
terutama dalam penyakit neuropsiakiatri. Kajian-kajian lepas telah banyak dilakukan 
ke atas sistem dopamin pusat sedangkan siasatan ke atas sistem dopamin dalam 
kalangan organ periferi masih terhad. Dalam kajian ini, kami mengkaji perbezaan di 
dalam ekspresi mRNA bagi reseptor dopamin DRD4 dan DRD5 di dalam sel limfosit 
dalam darah periferi dalam kalangan subjek lelaki Melayu dengan pergantungan 
campuran jenis opiat dan peransang jenis amfetamin yang sedang menjalani terapi 
gantian methadone berbanding lelaki Melayu yang sihat bertindak sebagai kawalan. 




dan ransangan jenis amfetamin dan 36 subjek kawalan telah direkrut daripada pelbagai 
tempat di Kuala Terengganu, Terengganu berdasarkan kriteria kelayakan dan 
pengecualian. Data demografi termasuk umur, tinggi, berat, indeks jisim badan (BMI) 
dan tekanan darah untuk semua peserta direkodkan. Kebenaran secara pemberitahuan 
dan bertulis diperolehi. Sampel darah diperolehi daripada setiap subjek. RNA telah 
diekstrak daripada sel limfosit. Ekspresi mRNA untuk reseptor DRD4 dan DRD5 di 
dalam sel darah limfosit periferi ditentukan menggunakan teknik "real-time PCR”. 
Data demografi untuk subjek-subjek dikira menggunakan ujian Mann Whitney. Nilai 
p<0.05 digunakan untuk perbezaan bererti. Terdapat perbezaan yang signifikan di 
antara subjek yang bergantung kepada dadah dan subjek kawalan untuk parameter 
umur dan tekanan darah sistolik sementara parameter-parameter lain tidak 
menunjukkan statistik yang signifikan. Aras ekspresi mRNA untuk reseptor DRD4 
dalam sel limfosit adalah menurun dengan signifikan di dalam subjek yang bergantung 
dadah berbanding dengan subjek kawalan (p=0.039). Walaubagaimanapun, aras 
ekspresi mRNA untuk reseptor DRD5 dalam sel limfosit subjek yang bergantung 
dadah kepada opiat dan peransang jenis amfetamin tidak menunjukkan statistik yang 
signifikan (p=0.0251). Sebagai kesimpulan, subjek yang bergantung dadah campuran 
opioid dan peransang jenis amfetamin yand sedang menjalani terapi gantian 
methadone mungkin mempamerkan corak yang berbeza pada ekspresi dopamin 
reseptor DRD4 dan DRD5 di dalam sel limfosit periferi. Kajian lanjut disarankan 




ASSESSMENT OF DOPAMINE RECEPTOR DRD4 AND DRD5 MRNA 
EXPRESSION IN PERIPHERAL BLOOD LYMPHOCYTES OF OPIOID & 
AMPHETAMINE TYPE STIMULANT DEPENDENT MALAY MEN 
UNDERGOING METHADONE MAINTAINENCE THERAPY 
 ABSTRACT 
In Malaysia and throughout the Asian region the mixed opioid and 
amphetamine type stimulants dependence is highly prevalent which has become a 
major health problem. Opioids and amphetamine-type stimulants (ATS) exert their 
effect by altering natural dopamine neurotransmission in the brain to achieve the 
ultimate goal of an extracellular hyper-dopamine state hence resulting drug reward 
effect.  Dopamine actions are mediated by specific G proteins coupled receptors of 
two distinct families; D1-like receptor subtypes (D1 and D5) and the D2-like receptor 
subtypes (D2, D3, and D4). Evidence from previous studies has suggested that 
peripheral dopamine systems reflect the central dopamine system’s activity and 
pathology, especially in neuropsychiatric diseases. Studies have been carried out 
widely on central dopamine systems, while investigation of dopamine systems in 
various peripheral organs is still limited. It has been reported that peripheral blood 
lymphocytes express dopamine in peripheral systems. In this study, we investigated 
the difference in the mRNA expression of the dopamine receptors DRD4 and DRD5 
in peripheral blood lymphocytes of ATS and opioid dependent Malay male subjects 
undergoing methadone maintenance treatment and healthy Malay male serving as 
control subjects. A total of 72 participants with 36 drugs dependent subjects and 36 
control subjects were recruited from various parts of Kuala Terengganu, Terengganu 




weight, body mass index and blood pressure of all participants were recorded. A 
questionnaire form was given to the drug dependent subjects to assess their drug 
addiction status. Informed and written consent was obtained, and blood samples were 
collected. RNA was extracted from lymphocytes. The mRNA expression of the 
dopamine receptors DRD4 and DRD5 in peripheral blood lymphocytes was assessed 
by real-time PCR method. The demographic data of the subjects were calculated using 
Mann Whitney Test. The p-value 0.05 was used for the statistical significance. There 
was a significant difference between drug dependent subjects and control subjects for 
age and systolic blood pressure parameters while other parameters were not 
statistically significant. The DRD4 mRNA expression level is significantly reduced in 
lymphocytes of drug dependent subjects compared to control subjects (p=0.039). 
However, DRD5 mRNA expression level in lymphocytes of drug dependent subjects 
was not statistically significant (p=0.251). In conclusion, drug dependent subjects on 
mixed opioid and ATS dependence undergoing methadone maintenance treatment 
may exhibit different patterns of dopamine receptors DRD4 and DRD5 mRNA 
expressions in the peripheral lymphocytes. Further studies are recommended to 




CHAPTER 1  
 
INTRODUCTION 
1.1 Drug Addiction 
Drug addiction is a major public health threat and social issue worldwide which 
includes addiction of opioids (both natural and synthetic opioid), methamphetamine, 
amphetamine type stimulant (ATS), cocaine, cannabis and other psychoactive 
substances (Low et al., 2016). According to World Drug Report 2019 (UNODC, 2019) 
cannabis is the most widely used drug worldwide while opioids and untreated hepatitis 
C maintain to be the most harmful, that account for two-thirds of the deaths due to 
drug use disorders. These drugs are being administered into the body through various 
routes including smoking, injection, tablets/pills, snorting/intra nasal and transdermal 
route. Injectors subjects were reported to have higher level of drug dependence and 
more likely to overdose. They also have higher risk of the serious blood-borne 
infection including HIV, Hepatitis B and Hepatitis C compared to those non-injector 
subjects (Mehta et al., 2011; Keen et al., 2014). 
Drug addiction is a chronic, relapsing and neurobiological brain disease involving 
multi factors including   genetic, neurodevelopmental, and sociocultural factors that 
are manifested by compulsive use of drugs despite harmful consequence (Volkow & 
Morales, 2015). The fifth edition of Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) classify drug addiction under section substance-related and 




clinically and functionally significant impairment, such as health problems, disability, 
and failure to meet major responsibilities at work, school, or home (Volkow et al., 
2016). This disorder is further classified into mild, moderate, or severe depending on 
severity level. While for addiction, DSM-5 referred addiction term as synonymous to 
the severe substance-use disorder class where there is substantial loss of self-control 
evident by compulsive drug taking instead of the desire to stop drug taking (Volkow 
et al., 2016).  
 Brain reward system which predominantly located in the limbic structures of the brain 
is a system that control and regulate cognitive function, learning ability, emotion and 
memory (Drozak & Bryła, 2005). The activation of the reward system will increase 
dopamine level which in turn causes the person to feel pleasure and motivated. Thus, 
this system is the major target of most drugs. Both natural and chemical stimuli that 
give pleasure effect activate the same site which is the reward system. However only 
natural activities are controlled by feedback mechanisms that activate aversive centers, 
whereas in the artificial stimuli there is no such mechanism occur. Therefore chronic 
intake of drugs can cause adaptive changes, sensitization or tolerance  in this system 
hence affecting the cognitive function which include decision making, learning as well 
as memory and behavior (Vetulani, 2001).  
1.1.1 Prevalence of drug addiction in Malaysia 
Malaysia has been facing a serious public health problem regarding drug addiction. It 
was initiated by the hippy culture in the 1970s and the Vietnam War which introduced 
cannabis and heroin to Malaysia (Singh et al., 2013). A cumulative total of 512,767 




between 1988 and 2017 representing about 1.6% of total Malaysian population 
(National Anti-Drug Agency (NADA), 2017). The real total of drug users may exceed 
more than half a million as the national database only reported individuals who have 
been arrested and convicted for illicit of drug use and sent for mandatory institutional 
rehabilitation (Vicknasingam et al., 2009).The annual number of reported drug addicts 
by the National Anti-Drugs Agency (NADA) in 2010 to 2017 is approximately 15,000 
to 30,000 per annum with a peak of  30,844 in 2016 and the least cases detected was 
in 2012 of 15,101 cases.  
 
Heroin maintains the first rank of the most frequently drug used every year since 2010 
to 2013 with a peak of 75.07% of total abused drugs in 2013. The percentage of heroin 
addiction per year shows a steady decline from 2014 to 2017 in which it reduced by 
half in 2017 which accounts for 39.1%. (National Anti-Drug Agency (NADA), 2017). 
 
The scenario is evidence by the growing problem of usage of amphetamine-type 
stimulants (ATSs) including crystal methamphetamine and various other 
methamphetamine and/or amphetamine-containing substances/pills in Malaysia and 
the surrounding countries (Chawarski et al., 2012). The rise of methamphetamine use 
in South East Asia has attracted major attention as it emerges as the world’s fastest-
growing methamphetamine market and the report that these drugs is the main drug of 
concern in South East Asia (SEA) countries (UNODC, 2019). According to Chawarski 
et al., (2012), ATS use in Malaysia has been insignificant before 1987. Over the next 
several years, the total ATS use increased slowly before spiking up after 1997. By 




that approximately 60% of opioid injection drug users report lifetime use of ATS with 
29% also reporting lifetime injection of ATS in many regions in Malaysia. Between 
2010 to 2017, it was observed that ATSs addiction ranging around 30-40% of total 
drug abused per year. The percentage started to rise steadily from 2014 and became 
more than half of total drug used in 2017 which exceeded heroin usage by 20.88% 
(National Anti-Drug Agency (NADA), 2017). The rising of ATSs usage also being 
evidenced by the increasing number of admissions in recent years for amphetamines 
use. In 2015, the total number for admission related with drug treatment was 6,032 
which opiates accounts for 71% (4,287) while the amphetamines use related admission 
was 1,571 accounting for 26% of the total in 2015 and about a 47% increase compared 
to 2014 (839 admissions). Of this total, methamphetamine (crystalline form) 
represented 77% (1,213 admissions) of the amphetamines-related treatment 
admissions in 2015 (Global SMART Programme & UNODC, 2017).  
 
Male continue to represent the majority (96.4%) of cumulative drug addict cases in 
Malaysia with a ratio of 1 female for every 26 males reported. About 41.7% of reported 
cases are amongst young people between the ages of 13-29 years old. In term of 
ethnicity, 80.6% of Malays, 7.5% of Chinese, and 6.8% of Indians were drug addict 
with other ethnics contributing 5.1% (National Anti-Drug Agency (NADA), 2017). 
1.1.2 Overview of opioid and opioid addiction 
Opioids include synthetic or naturally occurring alkaloid (benzylisoquinoline 
alkaloids) found in opium poppy plant (Manglik et al., 2012). Figure 1.1 and 1.2 




that stimulate brain’s opioid receptors, a group of receptors that give pain and euphoria 
perceptions which also involved in the breathing regulation (Waldhoer et al., 2004). 
Of all, morphine and heroin are the most known and used opioids while others include 
methadone, buprenorphine, codeine, tramadol, oxycodone and hydrocodone 
(UNODC, 2019). They are prescribed clinically for its analgesic properties and in 
treating opioid dependence. Excessive opioid used or in absence of proper medical 
supervision, can lead to fatal respiratory depression (UNODC, 2013). Opioids are 
being administered through injection, oral tablets and snorting. It also available in 
liquid, solid and powder form (Butler et al., 2011). Apart from its powerful analgesic 
effects, opioid intake also may induce relaxation and ‘high’ feeling as well as other 
side effects that include physical dependence, tolerance, respiratory depression, 
sedation, constipation, nausea, and death (Bruehl et al., 2013). 
 
Opioid acts by directly binding and activating opioid receptors chiefly μ-opioid 
receptor which mediates its most potent analgesic and addictive effects. μ-opioid 
receptor activation leads to two different signaling pathways. First through the 
heterotrimeric G-protein Gi, resulting in sedative and analgesic properties including 
physical dependence and euphoria. Secondly is through arrestin signal pathway which 
is linked to opioid side effects such as tolerance, constipation and respiratory 
suppression (Huang et al., 2015). The rewarding properties of opioid is achieved by 
indirectly elevating of post synaptic dopamine level in ventral tegmental area (VTA) 
which is considered as rewards system center. Activation of μ-opioid receptor results 
in inhibition of γ-aminobutyric acid (GABA)ergic normal inhibitory tone, leading to 
increase in dopaminergic neurons firing rate hence increasing dopamine level in 
























Most drugs of abuse including ATS and opioid exert trigger various mechanisms of 
actions in CNS system (including direct, indirect and multiple actions), hijacks the 
normal brain-reward circuitry in which natural dopamine neurotransmission is altered, 
to achieve the ultimate goal of extracellular hyperdopamine state (Daberkow et al., 
2013).  Dopamine is an extremely important neurotransmitter that mediates the 
reinforcing and rewarding effects in our body. Repeated exposure and administration 
of illicit drugs produces persistent adaptive changes in structural dopaminergic neuron 
and neuroadaptations in reward and reinforcement circuits, all of which involving in 




1.1.3 Overview of amphetamine type stimulant (ATS) and ATS addiction 
Amphetamine type stimulants (ATS) are manufactured composite that consist of two 
main sub-type amphetamine-type and ecstasy-type substances. Figure 1.3 shows, the 
chemical structure of amphetamine (C9H13N). Amphetamine group substances include 
amphetamine, methamphetamine and their derivatives, such as methcathinone, 
fenetylline, and methyl-phenidate (UNODC, 2015). Methamphetamine (street name 
frequently known as “crystal”, “glass”, “speed,” “ice,”) is being manufactured simply 
in illicit laboratories from readily accessible, cheap elements. Its chemical properties 
consist of ten carbon molecules, fifteen hydrogen molecules and one nitrogen 
molecules (C10H15N) (Figure 1.4). Ephedrine or pseudoephedrine are the most 
commonly used precursors for methamphetamine synthesis (Colfax et al., 2010). 
Amphetamine group substances are being prescribed for a number of clinical 
conditions under strict rules and regulation (Schifano & Naidoo, 2010).  
Esctasy group substances are synthesized from amphetamine derivatives, including 
methylenedioxy-methamphetamine (MDMA) and MDMA-like drugs. They are 
classified as ‘entactogens’ with no therapeutic use has been recognized so far.  
Unlike opioid which commonly being administered by injection route, amphetamine-
type stimulants are available in various form including tablets, crystalline and liquid 
which can be smoked, snorted, injected, or used per rectal (Chooi et al., 2017). ATS 
administration, particularly the amphetamine-group substances render the users being 
euphoric, experience heightened confidence level and lead to increase alertness, 
arousal, libido, energy levels and physical strength. Besides, ATS also raise heart rate, 




disorder may lead to serious complication including neurological damage to brain, 
acute renal failure and toxic effect to cardiovascular system. (Albertson et al., 1999; 





























ATS is a potent direct CNS stimulant that produces its rewarding effects by inducing 
a state of hyper-dopamine level extracellularly through three major mechanisms 
(Calipari & Ferris, 2013). First it inhibits dopamine uptake competitively by being 
dopamine transporter (DAT) substrate; second, it promotes dopamine release into the 
cytoplasm and out of vesicle; and third, independently to action potential induction to 
dopamine vesicular release, it promotes DAT to reversely transport dopamine into the 
synaptic cleft release (Goodwin et al., 2009). It has been observed that ATS acts as 
powerful agonist for trace amine-associated receptor 1 (TAAR1) TAAR, where 
binding of amphetamine to this receptor lead to brain monoamines regulation 
including dopaminergic activity modulation (G. M. Miller, 2011). 
 
1.1.4 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 
Diagnostic and statistical manual of mental disorders (DSM) is the standard and 
manual used by clinicians and researchers for clinical diagnosis, research, policy, and 
reimbursement purpose which published by American Psychiatric Association (APA). 
APA is a national medical specialty society participated by more than 37,000 physician 
members who specialize in the diagnosis, treatment, prevention and research of mental 
illnesses, including substance use disorders. DSM has been reviewed five times since 
the first edition of DSM which was released in 1952. The most recent edition of the 
DSM (5th edition) was published on May 18, 2013 at the 166th Annual Meeting of the 





DSM-5 classify drug disorder under chapter of “Substance-Related and Addictive 
Disorders” that which merges substance abuse and substance dependence categories 
in DSM-IV into one disorder. Substance use disorder is diagnosed according to the 
presence of more than two symptoms from a list of 11 which include drug craving 
symptoms. Other symptoms include hazardous use of the drugs, social/interpersonal 
problems related to use, neglected major roles to use, withdrawal, tolerance, use larger 
amounts/longer, repeated attempts to quit/control use, much time spent using, physical 
/ psychological problems related to use and activities given up to use (Brien et al., 
2013).  
1.1.5 Methadone maintenance therapy 
Methadone maintenance was first discovered by Dole and Nyswander in 1960s in USA 
which later became model for opioid dependence substitutional therapy worldwide 
(Courtwright, 1997). Consistent evidence through extensive research had revealed the 
effectiveness and efficacy of methadone maintenance treatment  in reduction of drug 
use, mortality rates (Gibson et al., 2008)  , transmission of Hepatitis C (Alavian et al., 
2013), HIV risk behaviours (Wong et al., 2003) and drug and property- related 
criminal behaviours (Russolillo et al., 2018). Besides, apart from being cost-effective, 
it helps to retain patients in treatment and significantly  improving quality of life in the 
physical, social ,psychological,and environmental aspects (Ali et al., 2018).    
In Malaysia, national harm reduction program was launched in 2004 to arrange and  
implement the harm reduction initiatives which include public education of drug use 
and HIV infection, introduction of needle & syringe exchange program (NSEP) and 




reduction programmes were rejected by Malaysia government as contradicting the aim 
of becoming a drug-free nation. However, extensive discussions and combined 
pressure from non-governmental organisations, medical expert and the public led to 
the approval of methadone maintenance therapy (MMT) as a pilot programme in early 
2005 and became officially started started with ten MMT centers  in October 2005 
with two of them operated in private sector (Ng et al., 2009; MyTOS Report, 2018).  
By December 2013 there were 811 MMT centres (446 government facilities and 365 
private setting) in this country that provided treatment for total of 65,259 opioid 
dependence patients (33444 in government facilities and 31, 805 in private settings) 
with 18 600 active patients (MyTOS Report, MOH, 2018). 
Methadone is a synthetic opioid with high bioavailability and readily absorbed from 
the intestine (Dale et al., 2004). It has long half-life which will result in longer duration 
of action and reaches stable-state plasma levels rapidly after recurrent administration. 
It is a direct µ, 𝛿 and ⲕ receptors agonist which indirectly will increase dopamine level 
extracellularly (Garrido & Trocóniz, 2000). Besides, it is a single dose on daily basis, 
taken orally and is effective to reduce cravings and withdrawal symptoms. This will 
help the patients to do their daily activities efficiently and get job hence improving 
their social functioning and stability (Baharom et al., 2012). At appropriate dose and 
right usage, methadone is non-toxic, non-sedating, with fewer side-effects mainly 
excessive sweating and constipation which slowly diminished over time (Ng et al., 
2009). Apart from the physical benefits, as it is being taken orally, the risk of 
transmission of bloodborne diseases will subsequently reduce. Taken together, the 
pharmacokinetics and pharmacodynamic properties of methadone make it an ideal 




1.2 Dopamine system and drug addiction     
1.2.1 Dopamine system 
Dopamine refers to 3,4-dihydroxy-L-phenylalanine (L-DOPA) derivative (Rub et al., 
2010). It is an important neurotransmitter which belongs to catecholamine group as it 
poses catechol structure (a benzene ring with two hydroxyl side groups) with one 
amine group attached to an ethyl chain (Figure 1.5). Dopamine presents in various 











1.2.1 (a) Central dopamine systems 
Dopamine is predominantly the most essential neurotransmitter in the brain. It forms 
approximately 80% of all brain catecholamine (Vallone et al., 2000). Apart of its well-
known cardinal role in brain reward system, dopamine also plays important function 
which determines by dopamine’s site release. Ventral midbrain (ventral tegmental area 
and substantia nigra) is the major brain dopamine’s location from which projects to 
four axonal pathways: (1) nigro-striatal; (2) mesolimbic; (3) mesocortical; and (4) 
tuberoinfundibular. 
 
The nigro-striatal pathway arises from the substantia nigra compacta (SNC) in the 
midbrain and projects to the dorsal striatum (caudate-putamen) (Qiu et al., 2019). This 
pathway regulates movement control and its degeneration results in Parkinson’s 
disease, observed as tremors, dyskinesia and rigidity. Two pathways which begins 
from the ventral tegmental area (VTA) project out to innervate different regions of the 
frontal cortex forming meso-cortical pathway. The other one innervates parts of limbic 
system, the ventral striatum (nucleus accumbens), and the olfactory tubercle (OT) 
forming mesolimbic pathway. The meso-cortical pathway is responsible for memory 
and learning center whereas the mesolimbic pathway is important for behavior and 
motivation regulation. The last pathway which is the tuberoinfundibular pathway 
arises from hypothalamus (arcuate nuclei) and perventricular cells, projects to median 
eminence of the hypothalamus, whereby dopamine is released into the perivascular 
spaces of the capillary plexus of the hypothalamic–hypophyseal portal system. Then 




action on lactotroph (Vallone et al., 2000; Ikemoto et al., 2010). Figure 1.6 
summarizes the dopaminergic pathway and its function. 
 
1.2.1 (b) Peripheral Dopamine System  
Apart from its prominent role in central nervous system, dopamine is an important 
catecholamine peripherally. As dopamine does not pass through blood brain barrier, 
the peripheral dopamine system has different signaling pathway of brain dopamine 
system which is closely linked to peripheral sympathetic nervous system. Synthesis of 
peripheral dopamine is both related and not related to neuronal properties as it is 
originated at least from three sources mainly from chromaffin cells in adrenal medulla, 
sympathetic neuronal fibers and additional source from amine precursor uptake and 
decarboxylation cells (APUD) cells (Rubí & Maechler, 2014). Plasma dopamine level 
is determined by sympathetic neurons activation and chromaffin cells of adrenal 
medulla which synthesize dopamine from L-3,4-dihydroxyphenylalanine (L-DOPA) 
as they express L-DOPA decarboxylase enzyme (Goldstein & Holmes, 2008). 
Meanwhile APUD cells are found in kidney pancreatic exocrine and endocrine cells, 
retinal cells, and peripheral leukocytes in which dopamine’s action varies according to 
the release site. In general, peripheral dopamine involves in regulation of sodium 
excretion and urine output in kidney as well as regulating blood pressure, respiration, 











1.2.2 Dopamine Receptors  
Dopamine plays its critical role in central nervous system and peripherally through 
actions mediated by specific receptors of multiple subtypes which include five distinct 
G protein-coupled receptor subtypes. Two D1-like receptor subtypes (D1 and D5) 
couple to the G protein Gs and activate adenylyl cyclase. The other receptor subtypes 
belong to the D2-like subfamily (D2, D3, and D4). They are prototypic of G protein-
coupled receptors that inhibit adenylyl cyclase and activate K+ channels (Missale et 
al., 1998).  
 
Dopamine receptors belong to the D1-like and D2-like receptor subtypes that are 
believed to be situated post-synaptic and pre-synaptic respectively. Central D2 
dopamine receptor activation regulate prolactin synthesis and release from anterior 
pituitary while D3 and D4 receptors are found in CNS area mediating cognitive 
function (Jaber et al., 1996).  
 
In cerebrovascular and renal system, D1-like receptors stimulation causes direct 
vasodilatation and reduce vascular resistance whereas D2-like receptors stimulation 
lead to indirect vasodilatation, by sympathetic vasoconstrictor tone inhibition. Besides, 
dopamine acts as potent positive inotropic agent towards cardiac muscle as well as 
induces diuresis and natriuresis. Dopamine receptor protein immunohistochemistry 
confirmed the localization of dopamine D1 and D5 receptors presence in the tunica 




associated with sympathetic neuroeffector junctions. Arrighi et al., (2009) reported 
that renal system expresses all the five distinct dopamine receptors subtypes.  
Human peripheral blood lymphocytes also express all dopamine receptors subtypes as 
well as vesicular dopamine transporters which is important in modulation the immune 
responses under physiological and pathological conditions (Buttarelli et al., 2011). 
Peripheral dopaminergic system D1-like and D2-like receptors are detected in 
pulmonary nerve trunk which are found on pulmonary afferents of immunoreactive 
fibers (Amenta et al., 2002). A concomitant stimulation of  D1 and D2 receptors is 
required, a phenomenon known as the "requisite" D1/D2 synergism  (Hasbi et al., 
2011). Study by Capper-Loup et al., (2002) also provide evidence that evocation of 
neural and behavioural sensitization to cocaine in rats only occurred in participation 
of both D1 and D2 receptors activation. On the other hand, the ability of D2 agonists 
to induce changes in basal ganglia single unit activity and spontaneous motor activity 
is dependent upon the presence of endogenous dopamine to stimulate D1 receptors 
(Walters et al., 1987). These observations revealed that synergism effect is only being 
generated in the presence of  both D1 and D2 receptors (Hasbi et al., 2011). In addition, 
D1-like receptors stimulation may reduce the seek reward motivation whereas the D2-
like receptors facilitate the addictive drugs rewarding effects (Li et al., 2006). 
1.2.2 (a) Dopamine receptor in peripheral blood lymphocytes  
Human peripheral blood lymphocytes (PBL) has been reported to synthesize 
endogenous dopamine including other related catecholamine; norepinephrine and 
epinephrine through tyrosine hydroxylase dependent pathway as well as expressing 




the dopamine receptors in the brain may be parallel to their homologous receptors in 
peripheral blood lymphocytes (PBLs) (Vousooghi et al., 2015). Interestingly, previous 
studies reported that central neurological disorders characterized by dysfunctional 
central  dopaminergic neurotransmission also concomitantly caused PBL 
dopaminergic pathway dysfunction (Ostadali et al., 2004).  
 
Studies in schizophrenia disorder had revealed a consistent evidence of the changes in 
PBL dopamine receptors expression in which D3 receptors up regulation were 
observed in most cases and closely related to the disease severity. Study by Kwak et 
al., (2001) that compared between dopamine receptors in PBL from treated and 
untreated schizophrenic patients and healthy subjects observed increased D3 receptor 
mRNA expression in PBL from unmedicated in comparison with medicated patients 
and healthy subjects. On the other hand, the decreased dopaminergic transmission in 
striatum that has been observed in Parkinson’s disease, also showed reduction in 
dopamine receptor expression in PBL which is consistent with the disease severity 
clinically (Nagai et al., 1996). 
 
In 2004, Czermak et al., (2004) observed reduced expression of D4 mRNA in PBL in 
long-term abstinent alcohol and heroin addicts which proposed dopamine imbalance 
is persistent in abstinent addicts. It has been detected that D3 receptor mRNA 
expression in PBL, is increased in heroin-addicted and methadone-maintained subjects 
while D4 mRNA expression in PBL declined in heroin-abstinent and heroin-addicted 
subjects. In heroin-abstinent subjects solely showed reduction of D5 mRNA 





Being relatively easily accessible and less invasive procedure to get blood cells instead 
of the technically difficulties in CNS in vivo study, these findings suggest that PBL 
dopamine system might represent an important promising tool to investigate the 
central dopamine pathologies as well as monitoring the efficiency of pharmacological 
and therapeutic intervention (Buttarelli et al., 2011). In addition, to date there is no 
available dedicated biological marker designed to objectively measure the drug 
addiction severity (Ersche et al., 2011). 
1.2.3 Dopamine and drug addiction  
Drugs of abuse is known to promote persistent neurobiological changes characterized 
by the compulsiveness of taking drug repeatedly hence causing craving and relapse. 
Being the brain reward centre, which acts as the common ultimate aim of majority of 
abused drugs, dopamine system (mesolimbic pathway) represents the most affected 
neurobiological systems of all (Czermak et al., 2004). Administration of drugs of 
abuse particularly stimulant drugs (cocaine, amphetamine, methamphetamine, etc) 
either directly or indirectly, causing elevation of dopamine level in post synaptic 
region which in turn mediate the reinforcement, euphoria and experience of pleasure 
(rewarding effects) (Daberkow et al., 2013).  
Researches on dopamine’s potential involvement in addiction has been dramatically 
expanded since 1970’s pioneered by Olds et al.,(1997) discovery that observed the 
positive reinforcement in rats characterized by self-stimulation repetition on certain 
brain region with electricity. Imperato (1988) then developed the brain micro-dialysis 
technique in rats and found that dopamine level in nucleus accumbens was increased 
